Identification of truncated RUNX1 and RUNX1-PRDM16 fusion transcripts in a case of t(1;21)(p36;q22)-positive therapy-related AML

This publication has 9 references indexed in Scilit:

• Novel RUNX1‐PRDM16 fusion transcripts in a patient with acute myeloid leukemia showing t(1;21)(p36;q22)
  Genes, Chromosomes and Cancer, 2005
• The leukemia-associated transcription repressor AML1/MDS1/EVI1 requires CtBP to induce abnormal growth and differentiation of murine hematopoietic cells
  Oncogene, 2002
• Results of treatment of children with refractory anaemia with excess blasts (RAEB) and RAEB in transformation (RAEBt) in Great Britain 1990–99
  British Journal of Haematology, 2002
• 21q22 balanced chromosome aberrations in therapy‐related hematopoietic disorders: Report from an International Workshop†
  Genes, Chromosomes and Cancer, 2002
• A novel gene, MEL1, mapped to 1p36.3 is highly homologous to the MDS1/EVI1 gene and is transcriptionally activated in t(1;3)(p36;q21)-positive leukemia cells
  Blood, 2000
• A novel syndrome of radiation-associated acute myeloid leukemia involving AML1 gene translocations
  Blood, 2000
• CBFA2(AML1) Translocations With Novel Partner Chromosomes in Myeloid Leukemias: Association With Prior Therapy
  Blood, 1998
• The chimeric genes AML1/MDS1 and AML1/EAP inhibit AML1B activation at the CSF1R promoter, but only AML1/MDS1 has tumor-promoter properties.
  Proceedings of the National Academy of Sciences, 1996
• Consistent intergenic splicing and production of multiple transcripts between AML1 at 21q22 and unrelated genes at 3q26 in (3;21)(q26;q22) translocations.
  Proceedings of the National Academy of Sciences, 1994